Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3503-6
Abstract: Chronic lymphocytic leukemia (CLL), a disorder for which B cell heterogeneity and increased cellular proliferation play central pathogenic roles, displays several genetic abnormalities that are associated with poor prognosis and have therapeutic implications. In this… read more here.
Keywords: cll; tp53 mutations; 17p deletion; mutation ... See more keywords
Relevance of newly acquired mutations to the prognosis of patients with relapsed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2020 at "Polish archives of internal medicine"
DOI: 10.20452/pamw.15446
Abstract: 473 serial FISH testing at diagnosis and relapse. Cy‐ togenetic evolution was defined as the acquisition or loss of a cytogenetic abnormality at the sec‐ ond FISH testing and was observed in 14 patients (48%).… read more here.
Keywords: medicine; del 17p; evolution; prognosis ... See more keywords
Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2017.7034
Abstract: Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell malignancy involving the spleen and bone marrow. Various cytogenetic abnormalities with prognostic value have been identified in SMZL. Complexity of karyotype, 14q aberrations, and TP53… read more here.
Keywords: marginal zone; zone lymphoma; idelalisib rituximab; splenic marginal ... See more keywords